LG Chem, Ltd

Products

FOTIVDA® (Tivozanib)

    • Product Name: FOTIVDA® (Tivozanib)
    • Chemical Name (IUPAC): 5-[(5-Pyridin-4-yl-1,3-thiazol-2-yl)amino]-2-(2-(dimethylamino)ethoxy)-4-(pyridin-2-yl)benzonitrile
    • CAS No.: 475108-18-0
    • Chemical Formula: C22H19ClN4O5
    • Form/Physical State: Capsule
    • Factroy Site:
    • Price Inquiry: sales6@ascent-chem.com
    • Manufacturer: LG Chem, Ltd
    • CONTACT NOW
    VTB
    Specifications
    HS Code 872951
    Generic Name Tivozanib
    Brand Name FOTIVDA
    Drug Class Tyrosine kinase inhibitor
    Indication Treatment of relapsed or refractory advanced renal cell carcinoma (RCC)
    Route Of Administration Oral
    Dosage Form Capsule
    Strengths Available 1.34 mg and 0.89 mg capsules
    Mechanism Of Action Selective inhibition of vascular endothelial growth factor receptors (VEGFR-1, -2, and -3)
    Manufacturer AVEO Pharmaceuticals, Inc.
    Fda Approval Date March 10, 2021
    Common Side Effects Fatigue, hypertension, diarrhea, decreased appetite, nausea, dysphonia
    Contraindications Known hypersensitivity to tivozanib or any component of the formulation
    Storage Conditions Store at 20°C to 25°C (68°F to 77°F)
    Prescription Status Prescription only

    As an accredited FOTIVDA® (Tivozanib) factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing FOTIVDA® (Tivozanib) packaging contains 21 capsules (1 mg), housed in a white blister pack within a teal and white box.
    Container Loading (20′ FCL) Container Loading (20′ FCL) for FOTIVDA® (Tivozanib): Securely packed, temperature-controlled, compliant with pharma safety and regulatory transport standards.
    Shipping FOTIVDA® (Tivozanib) should be shipped at controlled room temperature, typically between 20°C to 25°C (68°F to 77°F). Protect from excessive heat, moisture, and direct sunlight. Ship in its original packaging to ensure stability and maintain product integrity throughout transit. Follow all regulatory guidelines for pharmaceutical products.
    Storage FOTIVDA® (Tivozanib) capsules should be stored at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F). Store in the original container to protect from moisture and light. Keep the container tightly closed and out of reach of children. Do not refrigerate or freeze.
    Shelf Life FOTIVDA® (Tivozanib) has a shelf life of 3 years when stored at 20°C to 25°C (68°F to 77°F).
    Application of FOTIVDA® (Tivozanib)

    Applications of FOTIVDA® (Tivozanib) in Industrial Manufacturing

    FOTIVDA® (Tivozanib), as a highly selective VEGFR tyrosine kinase inhibitor, has a specialized industrial profile primarily in the field of pharmaceutical raw material synthesis. Our production supports advanced integration into pharmaceutical, research reagent, and high-purity reference material manufacturing, meeting stringent industry standards. Below, we detail the core downstream applications relevant to actual industry users.

    1. Pharmaceutical API Manufacturing for Oncology Therapeutics

    Tivozanib, produced to GMP standard, functions directly as the active pharmaceutical ingredient (API) in targeted cancer therapeutics. Downstream pharmaceutical companies use it in anti-angiogenic drug formulations for renal cell carcinoma. Production requires precise crystalline form and purity control, with comprehensive release testing to align with monographs and regulatory filings. Scaling from pilot to large batch involves tailored wet granulation and compaction steps to achieve uniformity before tableting or encapsulation, preserving chemical stability and particle morphology. End use focuses on finished prescription drugs for regulated oncology markets.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    2. Reference Standard Production for Analytical Laboratories

    Tivozanib produced at the highest purity is essential for use by certified reference material (CRM) and secondary standard manufacturers. These materials anchor regulatory and in-house quality control tests including HPLC, LC/MS, and impurity profiling in pharmaceutical and clinical labs. Purity control at ppm impurity levels and solid-state characterization ensures traceability to primary standards or pharmacopoeial requirements. Small batch isolation and vacuum drying techniques preserve sample integrity free of excipient or binder influence, supporting reproducible calibration of analytical equipment downstream.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    3. R&D Active Compound for Preclinical Drug Discovery Programs

    Drug development CROs and biotech firms require small-scale GMP or GLP-compliant tivozanib as an investigational compound for screening, in vivo animal studies, and cellular assays. Our controlled synthesis batches provide consistent impurity profiles, crucial for valid comparability during early research. Formulation development teams may prepare solutions or suspensions for pharmacokinetics or mechanism-of-action studies, while maintaining traceable documentation for regulatory support files. The downstream process may involve sterile filtration or microdosing, tightly monitored to preserve chemical structure and bioactivity as required for IND packages.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    4. Ingredient for Companion Diagnostic Kit Manufacturing

    Manufacturers of diagnostic kits for oncology may require tivozanib as a functional component in detection systems designed to monitor VEGFR pathway activity. Such applications use high-purity material as a calibrant or competitive inhibitor in ELISA, immunoassay, or in vitro diagnostic (IVD) workflows. The industrial process involves precision weighing and dissolution in buffer matrices, followed by sterile filtration and filling into test cartridges. Documentation and batch traceability are mandatory to secure CE-IVD marking or FDA 510(k) clearances for diagnostic products. Stability validation extends to packaging format and shelf-life testing in accordance with regional regimens.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    Free Quote

    Competitive FOTIVDA® (Tivozanib) prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8618018036652 or mail to sales6@ascent-chem.com.

    We will respond to you as soon as possible.

    Tel: +8618018036652

    Email: sales6@ascent-chem.com

    Inquiry

    Get Free Quote of LG Chem, Ltd

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    FOTIVDA® (Tivozanib): Opening New Paths for Renal Cell Carcinoma Therapy

    Direct Experience from the Manufacturing Floor

    Developing FOTIVDA® (Tivozanib) from raw chemistry to a finished medicine stands as a demanding process, shaped by years of close work between chemists, process engineers, and quality controllers. Every batch forged in our lines draws on the technical depth that only comes from continuous improvement and deep familiarity with regulatory standards. Watching Tivozanib move from kilo-lab to industrial scale, our teams face the real-world challenges of batch integrity, purity thresholds, and yield optimization. These aren’t theoretical milestones. They drive hard decisions on process adjustments, solid-state stability, and impurity profiling each week, not just at the launch of a product line.

    Understanding Tivozanib’s Purpose and Unique Action

    We designed Tivozanib to target renal cell carcinoma, a tumor type too often marked by poor prognosis and diminishing responses after first-line therapy. Working as a tyrosine kinase inhibitor that focuses on the vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), this compound disrupts the signals driving blood vessel growth inside tumors. Our experience in scaling its production illuminates how its selectivity for VEGFR distinguishes it from other multi-kinase products. Where broader spectrum agents often hit other targets leading to side effects like hair loss or hand-foot syndrome, Tivozanib’s tighter focus reduces these off-target events. This single mechanism directly reflects careful design starting from synthetic route all the way through API crystallization.

    Early in development, our labs evaluated dozens of kinase activity profiles before engineers locked in this route. Having walked the manufacturing floors, I’ve seen those real differences impact the amount of post-production cleanup, bioanalytical assays, and environmental burden. The result is a consistent, highly pure API forming the backbone of a solid oral dosage form—each step measured by high-performance liquid chromatography, mass spec, and impurity tracking rather than hope or speculation.

    Pursuing Consistency in Every Batch

    Renal cell carcinoma can recur even after surgery or other interventions. Oncologists need a therapy that delivers consistent blood levels, reliable pharmacokinetics, and a predictable safety profile. Our daily work ensures FOTIVDA® tablets match their label with every batch. Controlling micronization, granulation, and final tablet coating isn’t theoretical for us; it determines whether the product achieves its goal for patients.

    Our plant’s real challenge is translating regulatory filings into smooth production flow every month—getting polymorphic form, moisture protection, and metal content checked and documented, as many chemists before me will attest. I often review batch release papers directly. Mistakes or corner-cutting are caught early, not allowed through. Deviations mean real consequences for downstream users, and that awareness informs every stage from weighing raw intermediates to final analytical sign-off.

    Model and Dosage Strength

    We produce FOTIVDA® as a 1.34 mg tivozanib capsule. This dosage, grounded in clinical trials specifically conducted with our formulation, benefits from a deliberate balance of bioavailability and tolerability. Earlier clinical models often overestimated the need for aggressive dose escalation, which produced more side effects. Guided by our manufacturing data, clinicians now rely on this 1.34 mg strength for improved adherence and reduced need for dose modification.

    The film-coated capsules shield the API from oxidation and humidity, which bears out through our accelerated stability study records. Each capsule contains well-defined excipients. We select these not only for inertness and compatibility but also because our granulation and coating lines record fewer process variances with them compared to competitors’ systems. Microbial control and extractables are tracked for every excipient lot, which helps keep our finished product safe from contamination concerns seen elsewhere in the market.

    How Tivozanib Differs on the Ground

    Each time we review data from competing tyrosine kinase inhibitors, several differences emerge. Many older agents act on a broad panel of kinases, which carries increased risk for hypertension, diarrhea, skin toxicity, and taste changes. Years of working in manufacturing underline the influence of clean, focused chemistry. Tivozanib keeps its inhibitory profile narrow, so the plant rarely sees metabolite spikes or surprise degradation products that frequently show up in plants synthesizing broader spectrum compounds.

    Formulating this molecule for oral dosing requires careful handling due to its moderate solubility in water. Our teams have spent months screening excipients and fine-tuning milling parameters to avoid content uniformity failures—a challenge faced by every manufacturer but especially pressing in high-potency oncology products. By using advanced blending and robust in-process checks, we avoid the dose variation that has complicated patient care in the past. Patients taking Tivozanib experience fewer unexpected disruptions caused by product inconsistency because the plant lives and breathes process discipline daily.

    Direct Feedback from the Field to the Mixing Tanks

    Often, manufacturing can seem remote from doctor and patient stories. Yet feedback through pharmacovigilance and clinician networks comes straight to our quality leads. We revise handling protocols and environmental controls, not because of abstract regulatory shifts but after seeing real issues—such as particulate conservation, dissolution rates, and even packaging robustness—affect outcomes in clinic studies. This practice creates a two-way flow: feedback shapes our operations, and the lessons from the line feed back to the medical community about how Tivozanib’s performance stacks up under real world demand.

    This direct exchange gives us practical insights. We recently upgraded process filtration after receiving field reports showing particle contamination from a capsule supplier elsewhere. Our plant staff then recalibrated sieve mesh and capsule closing torque to bring the risk towards zero in-house. Such adjustments don’t show up in glossy marketing brochures, but over time, they transform our confidence in each shipment.

    Learning from Industry Missteps

    Manufacturers have watched the consequences of erratic batch quality in competitors’ kinase inhibitors—recalls, warnings for impurity levels, and off-label toxicity events. Often these issues trace back to raw material sourcing, lack of hands-on process validation, or skipping critical stress tests. Our company’s response comes from lessons learned over years.

    We stick with well-vetted suppliers for key intermediates, maintain stability chambers that mimic transport challenges, and run pilot batches under real-world temperature swings. It takes more time, but every operator, chemist, and analyst here knows cancer patients depend on that last line of process reliability. The work carries weight, even beyond checklists, and each improvement builds on months of technical troubleshooting, not spreadsheets or slogans.

    Addressing Supply Chain and Security Pressures

    Securing a steady stream of FOTIVDA® capsules means not just scaling output, but also planning for shortages, regulatory hurdles, and unforeseen plant stoppages. Our chemical supply chains stretch across regions. Geographic disruptions—floods, customs delays, transport strikes—call for contingency stocks and quick lot requalification. We leverage direct relationships with excipient and intermediate producers, shaped by years of mutual transparency.

    Tivozanib’s complex synthesis—marked by multiple catalytic steps, tight purification windows, and careful solvent recovery—has forced us to map out backup vendors for every critical stage. Each time we run a mock recall or simulate a transport failure, new process tweaks emerge. Such exercises keep staff alert and highlight the real costs of lapses, which in pharma manufacturing translate directly into lives affected.

    Quality Systems Built by the Teams Who Use Them

    Some companies try to optimize by outsourcing parts of the process or cycling through short-term labor in the plant. Our focus has always leaned towards keeping operators, analytical staff, and quality controllers closely involved—before, during, and after every production run. Problems get resolved quickly because the same people who make the batch check it, track deviations, and lead the root cause analysis when something doesn't look right. I’ve seen processes stabilized precisely because line staff can cite firsthand why each quality check exists.

    Electronic batch records, trackable operator interventions, and regular site audits help maintain data integrity. These aren’t just records for regulatory inspection but living tools for catching problems and refining our approach. Training for new hires centers around understanding the science behind each action—why we weigh to the decimal, why we keep water activity low during granulation, and what a single out-of-spec reading means for an entire shipment.

    Environmental Considerations and Responsible Production

    Manufacturing medicines at scale involves responsible solvent use, waste minimization, and emissions reduction. Our chemical engineering leads have spearheaded green chemistry initiatives not out of abstract obligation but after auditing plant emissions and local water tests. Each tivozanib batch requires solvent choices that minimize hazardous byproducts, and we design our distillation and washing steps to capture, recycle, and properly dispose of residual chemicals.

    Our plant tracks environmental metrics real-time. Recent investments bring solvent recovery rates above 95%, keeping emissions lower than regional and global norms. We continually tweak process steps to avoid producing unnecessary acid/base waste streams, and where necessary, batch treat effluents to prevent local impact. This direct engagement with our own environmental footprint sets Tivozanib production apart from plants that only address these issues during periodic inspections or compliance reviews.

    Research, Process Improvement, and Ongoing Challenges

    Getting to the stage of steady-state, high-quality FOTIVDA® production took years of pilot work—optimizing solvent volumes, filtration step timing, temperatures, and drying cycles. Our teams logged hundreds of control runs, using inline sensors to track critical process parameters in real time. Each control tweak reflects patient experience in real clinical trials, not just numbers in a lab notebook.

    The tough part isn’t just achieving that process, but maintaining it with every new batch, lot, and shipment, year after year. New regulations, new supplier profiles, and new data on drug stability all feed back to the plant in a relentless feedback loop. We’ve learned not to rely on yesterday’s solutions—each audit, every batch failure, every field complaint brings another chance to question whether our process still serves patients safely and efficiently.

    Looking Forward While Honoring What Works

    As we assess pipeline compounds or consider site expansion, the foundation built in FOTIVDA® manufacturing serves as a yardstick. The knowledge forged in bringing this molecule to market has changed our team’s thinking about everything from risk management to collaborative batch review. Human error, weather events, or supply hiccups all challenge our daily workflow, but inside our plant this mindset equates setbacks with opportunities for shared learning and improvement.

    The global oncology landscape keeps evolving, with new competitors and new therapeutic approaches promising more options. What doesn’t change on our lines: commitment to translating each lesson from partner clinics, regulators, and our own control data back into manufacturing reality. Each bottle, each batch, every tablet reflects not only chemistry, but also the drive and responsibility felt across our entire enterprise.

    Patient-Centered Motivation at the Heart of Production

    Every technical detail, every compliance paper, and every operator instruction sheet we produce traces back, at its core, to one goal: delivering predictable, reliable, and high-quality medicine to people facing renal cell carcinoma. The expertise and discipline inside our walls matter less for their own sake than for their effect in real clinics and homes.

    We know families and physicians depend on Tivozanib to meet their needs after other treatments lose effectiveness. That’s why each process, improvement initiative, and corrective action is measured against its impact for those users. From raw chemical selection to finished packaging seal, every choice reflects vigilance, care, and an acceptance that excellence in oncology medicines is not just policy, but a daily, lived practice. No batch leaves our floor until it meets those standards, carried forward by a team that never overlooks the meaning in every step from reactor to patient bedside.